Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 14/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.39 |
| ▸ | MMP9 | P14780 | 3/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5662403 | 0.96 | PDK2 (0.39) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL5660864 | 0.96 | PDK2 (0.39) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL24257912 | 0.92 | PDK2 (0.48) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL5498540 | 0.92 | PDK2 (0.40) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL15165488 | 0.92 | PDK2 (0.48) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL536401 | 0.91 | MMP2 (0.46) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL28942264 | 0.91 | MMP2 (0.46) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL16501148 | 0.91 | MMP2 (0.39) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL26058207 | 0.91 | PDK2 (0.41) | PDK2MMP2MMP9MMP8MMP13 | |
| SCHEMBL27625534 | 0.91 | PDK2 (0.36) | PDK2MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8319213-B2 | Aryl-aryl dendrimers | ISIS INNOVATION LIMITED (GB) | 2012-11-27 | — | — | US | disclosed |
| US-20110272688-A1 | ARYL-ARYL DENDRIMERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2011-11-10 | — | — | US | disclosed |
| US-7960725-B2 | Aryl-aryl dendrimers | ISIS INNOVATION LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-20100127251-A1 | Aryl-Aryl Dendrimers | ISIS INNOVATION LIMITED (GB) | 2010-05-27 | — | — | US | disclosed |
| US-7632576-B2 | Aryl-aryl dendrimers | ISIS INNOVATION LIMITED (GB) | 2009-12-15 | — | — | US | disclosed |
| US-20040169463-A1 | Aryl-aryl dendrimers | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1362382-A1 | ARYL-ARYL DENDRIMERS | ISIS INNOVATION LIMITED (GB) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002067343-A1 | ARYL-ARYL DENDRIMERS | ISIS INNOVATION LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100127251-A1 | Aryl-Aryl Dendrimers | CLTB, AHR, CD22 | PDK2 1266/4885MMP2 4542/4885MMP9 4768/4885 |
| US-20110272688-A1 | ARYL-ARYL DENDRIMERS | CD22, CLTB, AHR | PDK2 1193/4885MMP2 4452/4885MMP9 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.